From 039a905aa59474735007c87e774e6cab5804a57b Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 12:53:43 +0000 Subject: [PATCH] extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare Pentagon-Agent: Ganymede --- ...t cost impact inflationary through 2035.md | 6 ++++ ...ients-undermining-chronic-use-economics.md | 6 ++++ ...just-clinical-factors-drive-persistence.md | 6 ++++ ...-novo-lilly-glp1-price-deals-medicare.json | 32 +++++++++++++++++++ ...mp-novo-lilly-glp1-price-deals-medicare.md | 17 +++++++++- 5 files changed, 66 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 329db7879..f191470bb 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -35,6 +35,12 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems. + +### Additional Evidence (challenge) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* + +The Trump Administration's November 2025 Medicare deal establishes $245/month pricing (82% below list) with narrow eligibility criteria requiring comorbidities (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD). This targets ~10% of Medicare beneficiaries—specifically the high-risk population where multi-organ protection creates compounding savings. Under capitation, MA plans bearing full risk would see the $245/month cost offset by reduced hospitalizations, delayed dialysis, and cardiovascular event prevention. The eligibility design transforms GLP-1s from inflationary to potentially cost-neutral for the covered population by selecting patients where downstream savings exceed drug costs. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 1f412e7f8..7a0d09880 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design. + +### Additional Evidence (extend) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* + +The Trump Administration's Medicare deal establishes a $50/month out-of-pocket cap for tirzepatide (Zepbound) starting April 2026, down from typical costs of $200-300/month. This 75-83% reduction in patient cost burden directly addresses the affordability barrier that drives discontinuation. The KB already documents that lower-income patients show higher discontinuation rates, suggesting affordability (not just clinical factors) drives persistence. The $50 cap may significantly improve the 15% two-year persistence rate by removing the primary financial barrier, though behavioral and side-effect factors remain. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index c8aa03417..513f33049 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se. + +### Additional Evidence (confirm) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* + +The Trump Administration's Medicare deal reduces patient out-of-pocket costs to $50/month (from typical $200-300/month), representing a 75-83% reduction in cost burden. This policy intervention directly tests the affordability hypothesis: if discontinuation rates improve significantly under the $50 cap, it confirms that cost—not just clinical factors—is a primary driver of persistence. The deal creates a natural experiment where the same drugs at dramatically different price points will generate comparative persistence data. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json b/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json new file mode 100644 index 000000000..1c0a27333 --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "narrow-eligibility-targeting-in-glp-1-coverage-improves-cost-effectiveness-under-capitation-by-selecting-patients-where-downstream-savings-exceed-drug-costs.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-creates-novel-policy-mechanism-that-bypasses-traditional-cms-rulemaking.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "narrow-eligibility-targeting-in-glp-1-coverage-improves-cost-effectiveness-under-capitation-by-selecting-patients-where-downstream-savings-exceed-drug-costs.md:set_created:2026-03-16", + "manufacturer-price-concessions-in-exchange-for-coverage-expansion-creates-novel-policy-mechanism-that-bypasses-traditional-cms-rulemaking.md:set_created:2026-03-16" + ], + "rejections": [ + "narrow-eligibility-targeting-in-glp-1-coverage-improves-cost-effectiveness-under-capitation-by-selecting-patients-where-downstream-savings-exceed-drug-costs.md:missing_attribution_extractor", + "manufacturer-price-concessions-in-exchange-for-coverage-expansion-creates-novel-policy-mechanism-that-bypasses-traditional-cms-rulemaking.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md b/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md index 4b112ae56..816110ff8 100644 --- a/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md +++ b/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md @@ -7,9 +7,13 @@ date: 2025-11-06 domain: health secondary_domains: [internet-finance] format: news -status: unprocessed +status: enrichment priority: high tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -45,3 +49,14 @@ On November 6, 2025, President Trump announced agreements with Eli Lilly and Nov PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage + + +## Key Facts +- Medicare GLP-1 payment demonstration begins July 2026 +- BALANCE Model in Medicaid launches May 2026 +- BALANCE Model in Medicare Part D launches January 2027 +- Oral Wegovy launching January 2026 at $149-$299/month +- TrumpRx general price for GLP-1s: $350/month +- Medicare/Medicaid negotiated price: $245/month for semaglutide and tirzepatide +- Medicare beneficiary out-of-pocket cap: $50/month for tirzepatide starting April 2026 +- Approximately 10% of Medicare beneficiaries expected to meet eligibility criteria